The studies were not powered to assess efficacy against disease caused by individual HPV types. ‡ Efficacy was based on reductions in HPV 31-related CIN 2/ 3 or AIS § Efficacy was based on reductions in HPV 31-, 33-, 52-, and 58-related CIN 2/ 3 or AIS ║ Includes assay-identified non-vaccine HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
Študije niso omogočale vrednotenja učinkovitosti proti boleznim zaradi posameznih tipov HPV. ‡ Učinkovitost temelji na zmanjšanju CIN 2/ 3 ali AIS zaradi HPV 31 § Učinkovitost temelji na zmanjšanju CIN 2/ 3 ali AIS zaradi HPV 31, 33, 52 in 58 ║ Vključuje s testom odkrite tipe HPV 31, 33, 35, 39, 45, 51, 52, 56, 58 in 59, ki jih cepivo ne vsebuje.